Table 1.
Samples used in sVNT assay
| Group | Time point | Legend | Sample # |
|---|---|---|---|
| SARS-CoV-2 convalescent | 30-60d | D30-60 Rec | 20 |
| SARS-CoV-2 convalescent | 180-270d | D80-270 Rec | 20 |
| SARS-CoV-2 convalescent | 365d | D365 Rec | 22 |
| BNT162b2 | Pre/1 M post | Pre-BB/BB | 30 |
| CoronaVac | Pre/1 M post | Pre-CC/CC | 30 |
| SARS-CoV-2 convalescent + BNT162b2 | 1 M post | SARS2 + B | 20 |
| SARS-CoV-2 convalescent + Coronavac | 1 M post | SARS2 + C | 20 |
| SARS-CoV-1 patient from HK + BNT162b2 | Pre/1 M post |
SARS1 + pre B SARS1 + BB |
7 7 |
| SARS-CoV-1 patient from HK + Coronavac | Pre/1 M post |
SARS1 + pre C SARS1 + CC |
2 2 |
| SARS-CoV-1 patient from GZ Sinopharm | 2018, 1 M, 3 M, 6 M post |
SARS1 + pre S SARS1 + SS 1 M SARS1 + SS 3 M SARS1 + SS 6 M |
10 6 5 2 |
| Coronavac (2 doses) + Coronavac booster | Pre/1 M post | D0 CC + C/D30 CC + C | 20 |
| CoronaVac (2 doses) + BNT162b2 booster | Pre/1 M post | D0 CC + B/D30 CC + B | 20 |
| BNT162b2 (2 doses) + Coronavac booster | Pre/1 M post | D0 BB + C/D30 BB + C | 20 |
| BNT162b2 (2 doses) + BNT162b2 booster | Pre/1 M post | D0 BB + B/D30 BB + B | 20 |
| Omicron infected (unvaccinated) | Acute/Recovered | No vaxx + Omicron Acute/Rec | 10 |
| Omicron infected vaccinated BNT162b2 | Acute/Recovered | B + Omicron Acute/Rec | 20 |
| Omicron infected vaccinated Coronavac | Acute/Recovered | C + Omicron Acute/Rec | 14 |
| High neut positive control | 1 | ||
| Medium neut positive control | 1 | ||
| WHO standard 20/136 | 1 | ||
| Naïve pre pandemic negative control | 30 |